Sample stability:
Units: U/mL
|
Reference interval: < 35 |
The sensitivity and specificity of the test depend on the cutoff level used.
Comparing ovarian carcinoma patients at diagnosis with patients with benign gynaecological diseases :
| cutoff value | sensitivity | specificity |
|---|---|---|
|
65 U/mL |
79% |
82% |
|
150 U/mL |
69% |
93% |
Uncertainty of Measurement: 6%
Principle : Electrochemiluminescence Immunoassay
Reagents: Roche Elecsys CA 125 II
Analyser: Cobas e801
Monitoring the treatment and predicting recurrence of ovarian cancer.
Not all ovarian cancers express CA 125.
CA 125 is not suitable as a screening test for use in primary diagnosis of tumours.
CA 125 concentrations of up to 60 U/mL may occur during normal menstruation.
Elevated levels may occur in other malignancies, pregnancy, or less frequently in non-malignant conditions such as liver disease, endometriosis, ovarian cysts, and peritoneal trauma (laparotomy). Gastrointestinal, bronchial and breast carcinomas are occasionally associated with elevated CA 125.
The half life of CA 125 is 5 days.
Emails to chemicalpathologist@adhb.govt.nz will receive priority attention from the on-call chemical pathologist.
If the query concerns a specific patient please include the NHI number in your email.
If email is not a suitable option, please contact the on-call chemical pathologist via Lablink (Auckland City Hospital ext. 22000 or 09-3078995).
Individual chemical pathologists may be contacted but will not be available at all times.
After-hours : contact Lablink (Auckland City Hospital ext. 22000 or 09-3078995) or hospital operator for on duty staff after hours.
Dr Samarina Musaad (Clinical Lead) : SamarinaM@adhb.govt.nz ext. 22402
Dr Cam Kyle: CampbellK@adhb.govt.nz ext 22052
Dr Weldon Chiu: WeldonC@adhb.govt.nz ext. 23427
Dr Campbell Heron: CHeron@adhb.govt.nz ext. 23427
Dr Sakunthala Jayasinghe: Sakunthala@adhb.govt.nz ext. 23427